Prof Siamak Daneshmand speaks to ecancer at ASCO GU 2023 about the cohort 3 interim analysis of THOR-2, a phase 2 study of the efficacy and safety of erdafitinib in patients with intermediate-risk non–muscle-invasive bladder cancer with FGFR3/2 alterations.
He explains the primary exploratory end point for the study was the disappearance of the marker lesion without any new lesions; if there is a remnant of the marker lesion, no viable tumour should be seen on histopathological examination. The key secondary end point was safety for intermediate-risk non–muscle-invasive bladder cancer patients.
Prof Daneshmand concludes that data from cohort 3 of THOR-2 demonstrated an efficacy in adult patients with intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations treated with erdafitinib. Safety data was also consistent with the known safety profile of erdafitinib.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
